Eterna Therapeutics (NASDAQ:ERNA) Trading 2.4% Higher

Eterna Therapeutics Inc. (NASDAQ:ERNA) was up 2.4% during mid-day trading on Wednesday . The company traded as high as $1.84 and last traded at $1.80. Approximately 2,190 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 8,718 shares. The stock had previously closed at $1.76.

Eterna Therapeutics Stock Performance

The firm has a market capitalization of $10.01 million, a price-to-earnings ratio of -0.44 and a beta of 4.49. The company has a debt-to-equity ratio of 3.03, a current ratio of 0.79 and a quick ratio of 0.79. The firm’s fifty day moving average is $1.85 and its 200 day moving average is $1.94.

Hedge Funds Weigh In On Eterna Therapeutics

Hedge funds have recently modified their holdings of the stock. Avidian Wealth Solutions LLC bought a new stake in Eterna Therapeutics in the first quarter worth $36,000. Sippican Capital Advisors raised its holdings in Eterna Therapeutics by 34.7% during the first quarter. Sippican Capital Advisors now owns 72,800 shares of the company’s stock valued at $175,000 after buying an additional 18,750 shares in the last quarter. Finally, Lake Street Advisors Group LLC acquired a new stake in shares of Eterna Therapeutics in the fourth quarter worth about $933,000. 70.55% of the stock is owned by institutional investors and hedge funds.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.